273 related articles for article (PubMed ID: 28314412)
21. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
[TBL] [Abstract][Full Text] [Related]
22. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
[TBL] [Abstract][Full Text] [Related]
23. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
Taymans JM
Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW
J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354
[TBL] [Abstract][Full Text] [Related]
25. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.
Estrada AA; Sweeney ZK
J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
Ding X; Dai X; Long K; Peng C; Andreotti D; Bamborough P; Eatherton AJ; Edge C; Jandu KS; Nichols PL; Philps OJ; Stasi LP; Wan Z; Xiang JN; Dong K; Dossang P; Ho MH; Li Y; Mensah L; Guan X; Reith AD; Ren F
Bioorg Med Chem Lett; 2017 Sep; 27(17):4034-4038. PubMed ID: 28774425
[TBL] [Abstract][Full Text] [Related]
27. Design and Synthesis of Pyrrolo[2,3-
Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
[TBL] [Abstract][Full Text] [Related]
28. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
29. Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
Tasegian A; Singh F; Ganley IG; Reith AD; Alessi DR
Biochem J; 2021 Oct; 478(19):3555-3573. PubMed ID: 34515301
[TBL] [Abstract][Full Text] [Related]
30. Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods.
Gancia E; De Groot M; Burton B; Clark DE
Bioorg Med Chem Lett; 2017 Jun; 27(11):2520-2527. PubMed ID: 28408230
[TBL] [Abstract][Full Text] [Related]
31. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
32. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.
Baidya AT; Deshwal S; Das B; Mathew AT; Devi B; Sandhir R; Kumar R
Bioorg Chem; 2024 Feb; 143():106972. PubMed ID: 37995640
[TBL] [Abstract][Full Text] [Related]
33. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.
Tang X; Xing S; Ma M; Xu Z; Guan Q; Chen Y; Feng F; Liu W; Chen T; Chen Y; Sun H
J Med Chem; 2023 Feb; 66(4):2282-2307. PubMed ID: 36758171
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of the WD40 domain dimer of LRRK2.
Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
[TBL] [Abstract][Full Text] [Related]
35. Screening for chemical modulators for LRRK2.
Mortiboys H
Biochem Soc Trans; 2016 Dec; 44(6):1617-1623. PubMed ID: 27913670
[TBL] [Abstract][Full Text] [Related]
36. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
[TBL] [Abstract][Full Text] [Related]
37. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
Estrada AA; Liu X; Baker-Glenn C; Beresford A; Burdick DJ; Chambers M; Chan BK; Chen H; Ding X; DiPasquale AG; Dominguez SL; Dotson J; Drummond J; Flagella M; Flynn S; Fuji R; Gill A; Gunzner-Toste J; Harris SF; Heffron TP; Kleinheinz T; Lee DW; Le Pichon CE; Lyssikatos JP; Medhurst AD; Moffat JG; Mukund S; Nash K; Scearce-Levie K; Sheng Z; Shore DG; Tran T; Trivedi N; Wang S; Zhang S; Zhang X; Zhao G; Zhu H; Sweeney ZK
J Med Chem; 2012 Nov; 55(22):9416-33. PubMed ID: 22985112
[TBL] [Abstract][Full Text] [Related]
38. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
Moore DJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
[TBL] [Abstract][Full Text] [Related]
39. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease.
Koshibu K; van Asperen J; Gerets H; Garcia-Ladona J; Lorthioir O; Courade JP
Pharmacology; 2015; 96(5-6):240-7. PubMed ID: 26382237
[TBL] [Abstract][Full Text] [Related]
40. Leucine-rich repeat kinase 2 and Parkinson's disease.
Kang UB; Marto JA
Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
